Bicara Therapeutics Past Earnings Performance
Past criteria checks 0/6
Bicara Therapeutics's earnings have been declining at an average annual rate of -22.8%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
-22.8%
Earnings growth rate
79.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -11.7% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Bicara Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -59 | 15 | 54 |
| 30 Jun 24 | 0 | -65 | 13 | 45 |
| 31 Mar 24 | 0 | -58 | 11 | 38 |
| 31 Dec 23 | 0 | -52 | 9 | 31 |
Quality Earnings: BCAX is currently unprofitable.
Growing Profit Margin: BCAX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if BCAX's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare BCAX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BCAX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: BCAX has a negative Return on Equity (-11.67%), as it is currently unprofitable.